(Q44769723)

6 December 2017

title

Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa (English)

1 reference

6 December 2017

0 references

0 references

1

Gregg N Milligan

1 reference

6 December 2017

3

Chin-Fun Chu

1 reference

6 December 2017

4

Christal G Young

1 reference

6 December 2017

Kristen L Dudley-McClain

series ordinal

2

object named as

Kristen L Dudley-McClain

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

6 December 2017

number of pages

9

1 reference

inferred from page(s)

published in

Virology

1 reference

6 December 2017

volume

318

1 reference

6 December 2017

issue

2

1 reference

6 December 2017

page(s)

507-515

1 reference

DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2.

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Immune protection against HSV-2 in B-cell-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Prevention and treatment of experimental herpes simplex virus encephalitis with human immune serum globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunized female mice against herpes simplex virus type 2 infection in the genital tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Prior herpes simplex virus type 2 infection as a risk factor for HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Antigen-specific T cells localize to the uterine cervix in women with genital herpes simplex virus type 2 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Acute and Latent Infection of Sensory Ganglia with Herpes Simplex Virus: Immune Control and Virus Reactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Immunity to vaginal infection by herpes simplex virus type 2 in adult mice: characterization of the immunoglobulins in vaginal mucus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

7 January 2021

Epidemiological Synergy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

7 January 2021

Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

7 January 2021

Neutrophils aid in protection of the vaginal mucosae of immune mice against challenge with herpes simplex virus type 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

7 January 2021

Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.10.010

7 January 2021

10.1016/J.VIROL.2003.10.010

Identifiers

DOI

1 reference

6 December 2017

1 reference